Lbp Am Sa Purchases 52,303 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX)

LBP AM SA increased its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 20.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 305,221 shares of the company's stock after purchasing an additional 52,303 shares during the period. LBP AM SA owned approximately 0.13% of BioNTech worth $27,793,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp increased its holdings in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after buying an additional 246 shares in the last quarter. Allianz SE acquired a new stake in shares of BioNTech during the fourth quarter worth approximately $90,000. Goodman Advisory Group LLC acquired a new stake in shares of BioNTech during the first quarter worth approximately $105,000. Tower Research Capital LLC TRC increased its holdings in shares of BioNTech by 61.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock worth $214,000 after buying an additional 713 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in shares of BioNTech by 7.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock worth $221,000 after buying an additional 128 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Down 0.9%

NASDAQ:BNTX traded down $1.03 on Friday, hitting $112.89. 521,908 shares of the company's stock were exchanged, compared to its average volume of 943,543. The firm has a 50-day moving average price of $103.56 and a 200-day moving average price of $106.81. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. BioNTech SE Sponsored ADR has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a market cap of $27.14 billion, a P/E ratio of -33.20 and a beta of 1.29.

Analyst Ratings Changes

Several research firms have recently weighed in on BNTX. The Goldman Sachs Group started coverage on shares of BioNTech in a report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective for the company. Morgan Stanley set a $133.00 price target on shares of BioNTech and gave the company an "overweight" rating in a report on Thursday. Citigroup reissued a "buy" rating and issued a $140.00 price target (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $138.00 price objective on shares of BioNTech in a research note on Wednesday, June 25th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $137.91.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.